Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 2;105(3):625–640. doi: 10.1002/cpt.1057

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Age‐related increase in the systemic exposure to drugs. A PK ratio of 1 indicates no difference between younger and older people having received the same drug dose. Ratios indicating 1.5‐fold and 2‐fold increase in the systemic exposure in the elderly are marked by the dotted and the right solid line, respectively. If more than one study was available for a drug‐enzyme/transporter combination, we calculated means of ratios and in these instances; error bars indicate minimum and maximum of mean estimates of the multiple studies. The big age effect for capecitabine was not reproduced in other studies. As seen, a significant increase in the systemic exposure in old age was seen particularly for some CYP2C19 and CYP2D6 substrates, while for the majority of drugs only a moderate age‐dependent increase between 1‐ and 1.5‐fold was found.